5-氟尿嘧啶与双嘧达莫联合对肾癌细胞生长的影响  

Effects of 5-fluorouracil in combination with dipyridamole on proliferation of renal carcinoma cell line in vitro

作　　者：苏泽轩[1] 倪梁朝[2] 钟玲[3] 丁泓文[1] 

机构地区：[1]暨南大学附属第一医院泌尿外科,广州510630 [2]深圳市中心医院 [3]暨南大学药学院

出　　处：《中华实验外科杂志》2006年第7期853-855,共3页Chinese Journal of Experimental Surgery

摘　　要：目的探讨5-氟尿嘧啶(5-Fu)与双嘧达莫(DPM)作用对肾癌细胞生长的影响。方法以人肾癌细胞系(RCC925)为研究对象,运用长春新硷(VLB；Velban)作为参照的有/无核苷酸体外条件培养体系来研究不同浓度5-Fu(0．6、6．0、60．0 mg/L)与DPM的作用。结果当DPM浓度不变时,不同浓度5-Fu(0．6、6．0、60．0mg/L)分别对应的肾癌细胞生长抑制率组间比较差异有统计学意义(P＜0．05)；当5-FU浓度不变时,不同浓度DPM(0、1．25、2．50、5．00、10．00mg/L)分别对应的肾癌细胞生长抑制率组间比较差异有统计学意义(P＜0．05)；而且6、60mg/L浓度的5- Fu与5mg/L DPM联合应用,与单用0．078mg/L VLB对肾癌细胞的生长抑制率比较差异有统计学意义(P＜0．05)。结论5-Fu与DPM联合应用可优化肾癌治疗。Objective To investigate the inhibitory effects of 5-Fu in combination with dipyridamole on the growth of renal carcinoma. Methords Renal carcinoma cell line （Rcc925） was used to compadatively study the inhibitory rate of the growth under non-nucleoside culture condition after cultured with RPMI 1640 fetal calf serum, there was manufactured signal-ceil with 0.25% trypsin for 48 hours, then continuous cultured 24hours in different concentration of 5-Fu （0.6, 6.0, 60.0 mg/L）, DPM （0, 1.25, 2.50, 5.00, 10.00 mg/L） and VLB （0.0078 、0.078,0.78 mg/L） with RPMI 1640 including 10% dialysis ox serum in final concentration. Results when the same leve concentrantion of DPM being stablity, the inhibitory rate the different concentrantion of 5-Fu kept significant difference respectively （P〈0.05） ; on the othe hand, when the same leva concentrantion of 5-Fu being stablity, the inhibitory rate the different concentrantion of DPM kept significant difference respectively （P〈0.05）, and the inhibitory rate of carcinoma cells in cultured with 6, 60 mg/L in combination with 5 mg/L DMP was significant difference compared with 0.78, 0. 078 mg/L VLB in sole use （P〈0.05）. Conclusion The efffect to carcinoma ceil in vitro with combination with 5-Fu and DPM was significantly more than the sole use of VLB.

关 键 词：肾肿瘤 5-氟尿嘧啶 双嘧达莫 

分 类 号：R737.11[医药卫生—肿瘤] R979.1[医药卫生—临床医学]